factually
Index/Topics/FDA Safety Recommendations for Anti-Amyloid Monoclonal Antibodies

FDA Safety Recommendations for Anti-Amyloid Monoclonal Antibodies

The FDA's safety recommendations for anti-amyloid monoclonal antibodies such as lecanemab and donanemab

Fact-Checks

1 result
Jan 22, 2026

What are the FDA safety monitoring recommendations for patients on anti‑amyloid antibodies like lecanemab and donanemab?

safety recommendations for anti‑amyloid monoclonal antibodies such as lecanemab (Leqembi) and donanemab (Kisunla) center on intensive imaging surveillance for (ARIA), pre‑treatment risk stratification...